YOLFTbeta
Flerie

Flerie

FLERIE · ST · Healthcare / Biotechnology

13.00SEK+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close13.00
Open12.50
Day Range12.40 – 13.00
52-Week Range15.60 – 36.93
Volume50.23K
Market Cap1.40B
P/E (TTM)0.00
Forward P/E0.00
EPS-9.48
Dividend Yield0.00%
Beta-0.44
50-Day Avg18.78
200-Day Avg24.79

About

Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm, Sweden with additional office in London, United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Ted Fjallman Ph.D.
  • Employees2
  • HeadquartersSkeppsbron 16, Stockholm, Sweden, 111 30, Sweden
  • Websitehttps://www.flerie.com

Leadership

  • Mr. Thomas Eldered M.Sc.Executive Chairman of the Board · b. 1960
  • Dr. Ted Fjallman Ph.D.Chief Executive Officer · b. 1978
  • Ms. Cecilia Stureborg von ScheeleCFO & Deputy CEO · b. 1972
  • Mr. José Manuel OchoaVenture Partner · b. 1961
  • Ms. Paula AnderssonOperations & Investor Relations Manager · b. 1987
  • Ms. Michaela GertzHead of IR & Senior Advisor · b. 1981
  • Mr. Mark Quick M.B.A.Partner · b. 1966
  • Dr. Carl-Johan Spak Ph.D.Senior Advisor · b. 1956
  • Mr. Carlos von Bonhorst M.D.Senior Advisor · b. 1957
  • Mr. Arvid Söderhäll Ph.D.Venture Partner

Financials

Income Statement

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue176.00K113.00K128.00K88.00K35.00K-097.50M100.00K8.80M
Growth (%)--35.80%+13.27%-31.25%-60.23%----99.90%+8700.00%
Cost of Revenue39.93M73.43M82.74M87.80M57.76M1.25M1.07M4.16M41.70M21.50M
Gross Profit-39.76M-73.31M-82.61M-87.71M-57.73M-1.25M-1.07M93.35M-41.60M-12.70M
Gross Margin-22589.77%-64880.53%-64539.06%-99672.73%-164940.00%--95.74%-41600.00%-144.32%
Operating Expense00000114.38M150.05M200.71M69.20M769.40M
Operating Income-39.76M-73.31M-82.61M-87.71M-57.73M-115.63M-151.11M-107.37M-110.80M-782.10M
Operating Margin-22589.77%-64880.53%-64539.06%-99672.73%-164940.00%---110.11%-110800.00%-8887.50%
EBITDA-39.50M-72.75M-81.06M-86.77M-56.11M-101.66M-99.15M-93.82M-225.90M-743.60M
EBITDA Margin-22445.45%-64378.76%-63326.56%-98605.68%-160317.14%---96.22%-225900.00%-8450.00%
Net Income-41.27M-72.76M-82.15M-87.77M-57.42M-103.04M-100.33M-95.27M-228.00M-756.90M
Net Income Margin-23451.70%-64388.50%-64178.13%-99742.05%-164051.43%---97.70%-228000.00%-8601.14%
Interest Expense1.70M-150.00K61.00K113.00K133.00K120.00K227.00K3.80M13.70M
Interest Expense % of Total Revenue968.18%-117.19%69.32%322.86%--0.23%3800.00%155.68%

Balance Sheet

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets194.49M126.87M86.42M129.09M61.18M445.20M351.34M299.39M4.22B3.40B
Total Liabilities17.02M22.13M21.93M22.58M11.86M11.16M17.38M60.50M25.30M20.30M
Total Equity177.47M104.75M64.49M106.50M49.33M434.04M333.96M238.88M4.20B3.38B
Cash193.23M125.06M83.03M126.79M53.83M428.45M344.93M294.27M865.10M540.20M
Total Debt--1.43M484.00K2.34M1.28M3.25M2.30M800.00K2.10M
Net Debt-193.23M-125.06M-81.60M-126.31M-51.49M-427.17M-341.68M-291.97M-864.30M-536.50M

Cash Flow

Currency: SEK2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-31.87M-68.19M-78.57M-85.08M-70.65M-124.06M-129.44M-37.98M-17.00M-28.10M
Investing Cash Flow-53.00K----909.00K---625.20M-19.80M-109.50M
Financing Cash Flow218.19M8.00K36.55M128.84M-1.40M486.39M-818.00K634.70M571.90M-195.50M
Capital Expenditure53.00K000909.00K000028.10M
Free Cash Flow-31.92M-68.19M-78.57M-85.08M-71.56M-124.06M-129.44M-37.98M-17.00M-28.10M
FCF to OCF100.17%100.00%100.00%100.00%101.29%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateDec 31, 2016Mar 31, 2017Jun 30, 2017Nov 17, 2017Feb 26, 2018May 17, 2018Aug 28, 2018Nov 19, 2018Feb 20, 2019May 6, 2019Aug 22, 2019Nov 27, 2019Feb 20, 2020May 7, 2020Aug 26, 2020Nov 25, 2020Feb 25, 2021May 5, 2021Aug 25, 2021Nov 24, 2021Feb 23, 2022May 16, 2022Aug 26, 2022Nov 23, 2022Feb 23, 2023May 24, 2023Aug 23, 2023Nov 28, 2023Feb 21, 2024Apr 26, 2024Jul 17, 2024Oct 16, 2024Jan 22, 2025Apr 16, 2025Jul 31, 2025Oct 22, 2025Jan 21, 2026Apr 14, 2026Jul 10, 2026
EPS Estimate---------------------------------------
EPS Actual-8.92-11.57-7.97-6.89-11.75-9.84-13.64-7.94-10.97-8.22-8.44-12.80-9.55-8.88-5.76-2.85-3.73-1.71-7.00-4.64-3.75-3.10-3.57-0.57-9.25-6.8714.78-6.23-17.33-0.01158.85-1.50-0.82-3.222.22-1.78-6.98-0.78-1.02
Surprise---------------------------------------
Timing-----------------------------After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap1.40B
Enterprise Value1.20B
Trailing P/E0.00
Forward P/E0.00
Price / Sales992.21
Price / Book0.44
EPS-9.48
Book Value39.15
Revenue (TTM)-5.60M
Gross Profit (TTM)-25.70M
EBITDA-40.30M
Profit Margin0.00%
Operating Margin-746.15%
Return on Equity-22.18%
Return on Assets-0.67%
Shares Outstanding86.70M
Shares Float22.43M
Beta-0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 15, 20268:7
  • Jul 12, 20241:100